Mitchell E. Taub
Observed names: M E Taub, M. Taub, M.E. Taub, ME Taub, Mitchell E Taub, Mitchell Taub, Taub, Mitchel E, Taub, Mitchell E. (author)
Institution: Boehringer Ingelheim (United States)
Observed institutions: AstraZeneca (United Kingdom), University of Southern California, F. Hoffmann-La Roche AG, University of Copenhagen, Merck & Co., Inc., Rahway, NJ, USA (United States), Biogen (United States), United States Food and Drug Administration, Boehringer Ingelheim (Germany), Center for Drug Evaluation and Research, Netherlands Organisation for Applied Scientific Research, Inserm, Merck KGaA, Darmstadt (Germany), Eli Lilly (United States), Washington State University Spokane, Pfizer (United States), Genentech, Novo Nordisk (Denmark), University of Washington, Hôpital Beaujon, University of Manchester, Bristol-Myers Squibb (United States), GlaxoSmithKline (United States), BD Biosciences (United States), Absorption Systems (United States), Sanofi (Germany), AstraZeneca (Sweden), Solvo Biotechnology (Hungary), Eisai (United States), Optivia Biotechnology (United States), Boehringer Ingelheim (United States), Simcyp (United Kingdom), Université Paris Diderot, Takeda Oncology (United States), Drexel University
ORCID: 0009-0002-0300-726X
Observed ORCID: 0009-0002-0300-726X
OpenAlex ID: A5024576356
